| Message: | We know that the anabolic properties of compounds are defined with reference to testosterone. Studies have shown that AC-262 is approximately 66% anabolic and 27% androgenic as testosterone. So, we can calculate that the ratio of anabolic to androgenic for AC-262 is 2.45:1.
RAD 140 has an anabolic to androgenic ratio of about 90:1 and LGD 4033 has an anabolic to androgenic ratio of about 10:1. We can see the anabolic to androgenic ratio of AC-262 SARM Not high.
https://www.sarmshgpharm.com/sarms-list/acp262536/top-quanlity-ac-262-sarm-for-sale-benefits-dosage-and-reviews/
Does this mean that AC-262 are not as effective as other SARMs?
No, because anabolic potency is measured in terms of the compound's own androgenic effect. When the anabolic to androgenic ratio of testosterone is 1:1, measuring a compound in a ratio of 2:1 does not mean that the compound is twice as effective as testosterone.
The anabolic potency indicates that the compound is highly anabolic while being low androgenic. This means improved performance with minimal androgenic side effects.
The potency of AC-262 is also related to its binding affinity in muscle and bone.
The AC-262 SARM has an affinity of Ki 5nm, the anabolic to androgenic ratio of Ligandrol is 10:1, but the binding affinity of Ligandrol is Ki 1nm.
This also does not mean that the AC-262 is more effective than the LGD 4033. LGD4033 is a full agonist of SARM and AC-262 SARM is a partial agonist of SARM. The effect of partial agonists is not as pronounced as that of full agonists, but this is not too much of a problem, because with mild SARMs such as AC-262 SARMs, the dose can be increased depending on actual bodybuilding conditions.
If the full agonist LGD4033 is better, but the partial agonist AC-262 will be milder and have fewer side effects.
As a kind of SARM, AC-262 targets androgen receptors in bones and muscles, which is beneficial to bodybuilding without affecting other organ functions.
|
my account
